VivoSeq
Other

Sensorineural Hearing Loss

15

Pipeline Programs↗

6

Active Trials↗

7

Companies Involved↗

Sensorineural Hearing Loss is an emerging landscape with 15 programs across 7 companies. The most active players are GSK, Sanofi, Frequency Therapeutics. 6 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

93/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

2 programs

Phase 1Sanofi logo

Sanofi

1 program

Phase 2F

Frequency Therapeutics

2 programs

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedEisai logo

Eisai

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

21

clinical trials

Completed13 · 62%
Recruiting4 · 19%
Terminated1 · 5%
Unknown status1 · 5%
Enrolling by invitation1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

21 trials

Immunity After Cochlear Implantation and Perilymph Molecular Profiles in Sensorineural Hearing Loss
Recruiting·UUniversity Hospital, Montpellier·N/A·NCT05670158·80 enrolled
Evaluation of Frequency Allocation Tables for Recently Implanted Single-Sided Deaf Cochlear Implant Users
Recruiting·NNYU Langone Health·Preclinical·NCT07039435·22 enrolled
Long-term Follow-up of a Cohort of Adult CI632D and CI632 Participants in the CLTD5759 CI-DEX Study
Recruiting·CCochlear·N/A·NCT06936449·19 enrolled
Neural Prediction to Enhance Language Outcomes in Children With Cochlear Implant
Recruiting·AAnn & Robert H Lurie Children's Hospital of Chicago·Preclinical·NCT05962359·700 enrolled
Noise Reduction With Hearing Aids
Not yet recruiting·NNYU Langone Health·Preclinical·NCT07700043·60 enrolled
Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
Enrolling by invitation·TTruway Health, Inc.·Phase 1·NCT07472023·120 enrolled
FX-322 in Adults With Acquired Sensorineural Hearing Loss
Completed·FFrequency Therapeutics·Phase 2·NCT05086276·142 enrolled
FX-322 in Adults With Severe Sensorineural Hearing Loss
Completed·FFrequency Therapeutics·Phase 1·NCT04629664·31 enrolled
Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
Completed·AAuris Medical AG·Phase 2·NCT00802425·210 enrolled
Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo
Completed·TThe First Hospital of Hebei Medical University·N/A·NCT07283562·100 enrolled
FX-322 in Adults With Stable Sensorineural Hearing Loss
Completed·FFrequency Therapeutics·Phase 2·NCT04120116·95 enrolled
Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
Completed·—·Phase 1·NCT06025097·70 enrolled
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
Completed·FFrequency Therapeutics·Phase 1·NCT04601909·30 enrolled
FX-322 in Sensorineural Hearing Loss
Completed·FFrequency Therapeutics·Phase 1/2·NCT03616223·23 enrolled
Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
Completed·JJames Baumgartner, MD·Phase 1·NCT02038972·11 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)